Search

Your search keyword '"Ignasi Figueras-Nart"' showing total 27 results
Start Over Author "Ignasi Figueras-Nart" Database OpenAIRE
27 results on '"Ignasi Figueras-Nart"'

1. Mucocutaneous Response to New Therapeutic Strategies in Behçet’s Disease: A Retrospective Cohort Study

Author

Carlos Moreno-Vílchez, Rosa Fornons-Servent, Xavier Solanich, Javier Narvaez, and Ignasi Figueras-Nart

Subjects
Malaltia de Behçet, Behçet's disease, Article Subject, Therapeutics, Dermatology, General Medicine, Terapèutica
Abstract

Mucocutaneous lesions are the most frequent symptoms of Behçet’s disease (BD). Recently, new therapies are being used to treat refractory cases, but the effect of these treatments on mucocutaneous manifestations has been scarcely reported. Our objective was to describe the mucocutaneous response to the different therapies used to treat BD in routine clinical practice. We retrospectively reviewed the clinical records of all patients diagnosed with BD seen at our institution between January 2010 and January 2022. Patients with BD without mucocutaneous manifestations were excluded. We included 109 patients diagnosed with BD: 51 males (46.8%) and 58 females (53.2%). The mean age at diagnosis was 31.58 years (standard deviation (SD) 12.110) and the mean time of disease evolution was 14.94 years (SD 11.094). Oral ulcers were the most frequent symptom present in 100% of patients, followed by genital ulcers (GU) in 76.1% of patients. Twenty-four patients (22%) had severe mucocutaneous symptoms (>12 lesions/year) before treatment. We found that among patients with GU there was a higher prevalence of episodes of posterior uveitis and venous thrombosis ( p = 0.011 and p = 0.045 , respectively). In our series, we observed a lower complete cutaneous response to colchicine in patients with GU, pathergy or severe mucocutaneous symptoms ( p < 0.05 ). Regarding the choice of a TNF-α inhibitor, we observed a lower prevalence of complete cutaneous response to adalimumab among patients with GU (53.3% complete response in patients with GU vs. 100% in patients without GU, p = 0.022 ), whereas no differences were found between clinical characteristics in the response to infliximab.

Published
2023
Full Text
View/download PDF

3. Frontal fibrosing alopecia in men: A multicenter study of 39 patients

Author

Andrea Combalia, Ignasi Figueras-Nart, Ramon Grimalt, María Librada Porriño-Bustamante, Virginia Velasco-Tamariz, Juan Francisco Mir-Bonafé, Ramon M. Pujol, Enrique Rodríguez-Lomba, Alejandro Lobato-Berezo, and Maribel Iglesias-Sancho

Subjects
Male, medicine.medical_specialty, business.industry, Frontal fibrosing alopecia, Lichen Planus, Alopecia, Dermatology, Scarring alopecia, medicine.disease, Lichen planopilaris, Fibrosis, Hair loss, Multicenter study, medicine, Humans, business
Published
2022
Full Text
View/download PDF

5. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

Author

José-Juan Pereyra-Rodríguez, Pedro Herranz, Ricardo Ruiz-Villaverde, Marta Elosua-González, Manuel Galán-Gutiérrez, Ignasi Figueras-Nart, Javier Miquel, Pablo de la Cueva, Esther Serra-Baldrich, Monica Munera-Campos, Gemma Melé-Ninot, Vicente Expósito-Serrano, Bibiana Perez, Amalia Serrano, Javier F Ortiz de Frutos, and José C Armario-Hita

Subjects
Dermatology
Abstract

Background Tralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13 inhibitor that specifically neutralizes IL-13 with high affinity. Objectives To determine the real-life short-term effectiveness and safety of tralokinumab treatment in patients with moderate-to-severe AD. Methods A multicentre retrospective study was conducted including adult patients with moderate-to-severe AD who started tralokinumab treatment from 1 April to 30 June 2022 in 16 Spanish hospitals. Demographic and disease characteristics, severity and quality of life scales were collected at the baseline visit and at weeks 4 and 16. Results Eighty-five patients were included. Twenty-seven patients (32%) were non-naive to advanced therapy (biological or Janus kinase inhibitors inhibitors). All included patients had severe disease with baseline Eczema Area and Severity Index (EASI) scores of 25.4 (SD 8.1), Dermatology Life Quality Index (DLQI) 15.8 (5.4) and peak pruritus numerical rating scale (PP-NRS) 8.1 (1.8) and 65% had an Investigator’s Global Assessment (IGA) of 4. At week 16, there was improvement on all scales. The mean EASI decreased to 7.5 (SD 6.9, 70% improvement), SCORing Atopic Dermatitis improved 64% and PP-NRS, 57%. Also, 82%, 58% and 21% of the patients achieved EASI 50, 75 and 90, respectively. The percentage of EASI 75 responders was significantly higher among the naive vs. non-naive groups (67% vs. 41%). The safety profile was acceptable. Conclusions Patients, with a long history of disease and prior multidrug failure, showed a good response to tralokinumab, confirming clinical trial results.

Published
2023
Full Text
View/download PDF

8. Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?

Author

Gemma, Melé-Ninot, Esther, Serra-Baldrich, Jorge, Spertino, Mar, Guilarte, Paula, Ribó González, Ramon, Lleonart-Bellfill, Ignasi, Figueras-Nart, Montserrat, Bonfill-Ortí, Nathalie, Depreux, Anna, Sala-Cunill, Isabel, Bielsa-Marsol, Carola, Baliu-Piqué, Verònica, Sanmartín-Novell, Xavier, Garcia-Navarro, Vicente, Expósito-Serrano, Diana, Garnica-Velandia, Maria Carmen, Diaz-Sarrió, Sara, Gómez-Armayones, Ignasi, Gich Saladich, and Ana, Giménez-Arnau

Subjects
Cross-Sectional Studies, Urticaria, Histamine Antagonists, Humans, Chronic Urticaria, Omalizumab
Abstract

The guidelines for the treatment of chronic spontaneous urticaria (CSU) recommend adding omalizumab to the treatment of patients with uncontrolled disease despite four-fold doses of second-generation antihistamines (AH). On the contrary, some studies revealed that omalizumab was effective without concomitant AH and several authors suggest tapering off AH when CSU is controlled with omalizumab.The aim of our study was to evaluate the use of AH during treatment with omalizumab in patients with CSU in real clinical practice.This was a multicentre cross-sectional and observational study conducted by the Catalan and Balearic Chronic Urticaria Network (XUrCB) based on a cohort of 298 CSU patients treated with omalizumab.In total, 23.5% of our patients decided themselves to stop taking AH during omalizumab treatment. The ratio of patients with CSU without concomitant inducible urticaria and the percentage of patients with a good response to omalizumab (UAS7≤6 and/or UCT ≥12) were higher in those who stopped taking AH.More studies are required to identify the phenotypic characteristics of patients responding to omalizumab as monotherapy in order to avoid overtreating with AH. Our study suggests that patients with CSU without concomitant inducible urticaria and those who achieve a good response to omalizumab tend to be controlled by omalizumab without AH. In order to establish guidelines on how to stop AH, further evidenced-based studies are required.

Published
2022

10. SEB-induced IL-13 production in CLA

Author

Lídia, Sans-De San Nicolàs, Ignasi, Figueras-Nart, Montserrat, Bonfill-Ortí, Carmen, De Jesús-Gil, Irene, García-Jiménez, Antonio, Guilabert, Laia, Curto-Barredo, Marta, Bertolín-Colilla, Marta, Ferran, Esther, Serra-Baldrich, Anna, Zalewska-Janowska, Yui-Hsi, Wang, Michael D, Howell, Ramon M, Pujol, and Luis F, Santamaria-Babí

Subjects
Memory T Cells, Enterotoxins, Interleukin-13, Th2 Cells, Humans, Th1 Cells, Dermatitis, Atopic, Skin
Published
2022

13. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis

Author

Lídia Sans‐De San Nicolàs, Ignasi Figueras‐Nart, Montserrat Bonfill‐Ortí, Carmen De Jesús‐Gil, Irene García‐Jiménez, Antonio Guilabert, Laia Curto‐Barredo, Marta Bertolín‐Colilla, Marta Ferran, Esther Serra‐Baldrich, Anna Zalewska‐Janowska, Yui‐Hsi Wang, Michael D. Howell, Ramon M. Pujol, Luis F. Santamaria‐Babí, [Sans-De San Nicolàs L, De Jesús-Gil C, García-Jiménez I] Grup d’Immunologia Translacional, Departament de Biologia Cel·lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, Spain. [Figueras-Nart I, Bonfill-Ortí M] Departament de Dermatologia, Hospital de Bellvitge, Universitat de Barcelona (UB), L’Hospitalet de Llobregat, Spain. [Guilabert A] Departament de Dermatologia, Hospital General de Granollers, Granollers, Spain, and Hospital General de Granollers

Subjects
Estafilococs daurats, enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::dermatitis::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::dermatitis atópica [ENFERMEDADES], Bacteria::Bacteria::Firmicutes::Bacillales::Staphylococcaceae::Staphylococcus::Bacteria::Bacteria::Staphylococcus aureus [ORGANISMS], Estafilococs, Pell--Malalties, Immunology, Skin and Connective Tissue Diseases::Skin Diseases::Dermatitis::Skin and Connective Tissue Diseases::Skin Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Dermatitis, Atopic [DISEASES], Immunology and Allergy, Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes [ANATOMY], Pell - Infeccions, Dermatitis atòpica, Bacteria::Bacteria::Firmicutes::Bacillales::Staphylococcaceae::Staphylococcus::Bacteria::Bacteria::Staphylococcus aureus [ORGANISMOS], células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T [ANATOMÍA]
Abstract

Atopic dermatitis; Cutaneous lymphocyte antigen; Skin infections Dermatitis atópica; Antígeno cutáneo de linfocitos; Infecciones de la piel Dermatitis atòpica; Antigen limfòcit cutani; Infeccions de la pell Staphylococcus aureus, memory skin-homing cutaneous lymphocyte-associated antigen (CLA)+ T cells and IL-13 constitute relevant play-ers in atopic dermatitis (AD) pathogenesis.1 Since circulating CLA+ T cells reflect cutaneous abnormalities present in human inflammatory skin diseases,2 an ex vivo coculture model made of purified circu-lating CLA+/− effector and central memory T cells and autologous lesional epidermal cells was established. We show a CLA-dependent production of IL-13 upon activation with staphylococcal enterotoxin B (SEB) that allows the differentiation of the Th2 high and Th2 low groups, with distinct clinical correlations between both groups, within a clinically homogeneous population of adult non-treated moderate-to- severe AD patients.

Published
2022

14. Anakinra-induced psoriasis in a patient with Schnitzler's syndrome

Author

Andrea Bauer-Alonso, Rosa Fornons-Servent, Clàudia Llobera-Ris, Rosa M. Penín-Mosquera, José Hernández-Rodríguez, and Ignasi Figueras-Nart

Subjects
Interleukin 1 Receptor Antagonist Protein, Urticaria, Rheumatology, Immunology, Humans, Psoriasis, Immunology and Allergy, Schnitzler Syndrome
Published
2022
Full Text
View/download PDF

15. Recomendaciones del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) de la AEDV en relación con la realización de pruebas epicutáneas durante la pandemia por SARS-CoV-2 (COVID-19)

Author

J.M. Carrascosa, M.A. Pastor-Nieto, I. Ruiz-González, J.F. Silvestre, L. Borrego, M.E. Gatica-Ortega, A.M. Giménez-Arnau, José Carlos Armario Hita, Leopoldo Borrego Hernando, José Manuel Carrascosa Carrillo, Susana Córdoba Guijarro, Laia Curto, Virginia Fernández Redondo, Ignasi Figueras Nart, Juan García Gavín, María Elena Gatica Ortega, Anna Giménez Arnau, Elena Giménez Arnau, Enrique Gómez de la Fuente, Ricardo González Pérez, Felipe Heras Mendaza, Marcos Hervella Garcés, Pilar Manrique Martínez, Pedro Mercader García, Francisco Javier Ortiz de Frutos, Javier Miquel Miquel, María Antonia Pastor Nieto, Mercedes Rodríguez Serna, Inmaculada Ruíz González, Araceli Sánchez Gilo, Paloma Sánchez-Pedreño Guillén, Javier Sánchez Pérez, Tatiana Sanz Sánchez, Esther Serra-Baldrich, Juan Francisco Silvestre Salvador, and Violeta Zaragoza Ninet

Subjects
Histology, epicutáneas, Contact, contacto, COVID-19, Dermatitis, General Medicine, telemedicine, Dermatology, Article, Patch testing, Pathology and Forensic Medicine
Abstract

Resumen Con el progresivo control de la pandemia por SARS-CoV-2, los miembros del Grupo Espanol de Investigacion en Dermatitis de Contacto y Alergia Cutanea (GEIDAC) realizan una propuesta sobre cuales van a ser los requisitos, las limitaciones y los condicionantes para reanudar el servicio en las unidades de dermatitis de contacto en un escenario en el que se presume la persistencia del virus, con episodios ocasionales o estacionales de exacerbacion. Se aconseja ajustar el numero de pruebas epicutaneas (PE) a las posibilidades de cada centro y la revision de los casos en lista de espera para priorizar a los pacientes en funcion de la gravedad y la urgencia. Se ofreceran, si es factible, metodos telematicos para los documentos relativos a las PE (informacion, pautas, documentos de consentimiento informado). De estar disponible, puede ofrecerse la opcion de realizar una primera visita telematica. Igualmente, en pacientes seleccionados puede llevarse a cabo una televisita en las visitas de lectura a traves de imagenes realizadas por el paciente o mediante una videovisita que permita visualizar el resultado de la exploracion. Estas acciones permitiran reducir el numero de visitas presenciales, aunque no el tiempo dedicado y asignado al facultativo para los actos medicos. Todas estas recomendaciones son sugerencias y se adaptaran a los requisitos y a las posibilidades de cada centro sanitario

Published
2020
Full Text
View/download PDF

16. Definition of Recurrent Chronic Spontaneous Urticaria

Author

E Serra-Baldrich, Xavier García-Navarro, Antonio Guilabert, Gemma Melé-Ninot, Vicente Expósito-Serrano, Ignasi Figueras-Nart, J. Spertino, Isabel Bielsa-Marsol, Laia Curto-Barredo, and Ana Giménez-Arnau

Subjects
chronic urticaria, medicine.medical_specialty, Hardware_MEMORYSTRUCTURES, Urticaria, business.industry, recurrent chronic spontaneous urticaria, MEDLINE, Dermatology, General Medicine, Omalizumab, lcsh:RL1-803, Chronic Disease, lcsh:Dermatology, Medicine, Humans, chronic spontaneous urticaria, Chronic Urticaria, business, Urticària, Chronic urticaria
Abstract

is missing (Short communication)

Published
2020

17. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine

Subjects
medicine.medical_specialty, Edema angioneuròtic, Urticaria, media_common.quotation_subject, Immunology, education, GA2LEN, Angioedema, Center, Excellence, Management, urticaria, centres of reference and excelence, immune system diseases, center, medicine, Immunology and Allergy, Center (algebra and category theory), Angioneurotic edema, skin and connective tissue diseases, media_common, udc:616.1, business.industry, angioedema, humanities, referenčni centri odličnosti, Medicine, Allergy, Family medicine, excellence, medicine.symptom, business, Global Allergy and Asthma European Network, Urticària, management
Abstract

This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.

Published
2020
Full Text
View/download PDF

18. Definition, aims, and implementation of GA

Author

Marcus, Maurer, Werner, Aberer, Rosana, Agondi, Mona, Al-Ahmad, Maryam Ali, Al-Nesf, Ignacio, Ansotegui, Rand, Arnaout, Luisa Karla, Arruda, Riccardo, Asero, Emel, Aygören-Pürsün, Aleena, Banerji, Andrea, Bauer, Moshe, Ben-Shoshan, Alejandro, Berardi, Jonathan A, Bernstein, Stephen, Betschel, Carsten, Bindslev-Jensen, Mojca, Bizjak, Isabelle, Boccon-Gibod, Konrad, Bork, Laurence, Bouillet, Henrik Balle, Boysen, Nicholas, Brodszki, Sigurd, Broesby-Olsen, Paula, Busse, Thomas, Buttgereit, Anette, Bygum, Teresa, Caballero, Régis A, Campos, Mauro, Cancian, Ivan, Cherrez-Ojeda, Danny M, Cohn, Célia, Costa, Timothy, Craig, Paulo Ricardo, Criado, Roberta F, Criado, Dorottya, Csuka, Joachim, Dissemond, Aurélie, Du-Thanh, Luis Felipe, Ensina, Ragıp, Ertaş, José E, Fabiani, Claudio, Fantini, Henriette, Farkas, Silvia Mariel, Ferrucci, Ignasi, Figueras-Nart, Natalia L, Fili, Daria, Fomina, Atsushi, Fukunaga, Asli, Gelincik, Ana, Giménez-Arnau, Kiran, Godse, Mark, Gompels, Margarida, Gonçalo, Maia, Gotua, Richard, Gower, Anete S, Grumach, Guillermo, Guidos-Fogelbach, Michihiro, Hide, Natalia, Ilina, Naoko, Inomata, Thilo, Jakob, Dario O, Josviack, Hye-Ryun, Kang, Allen, Kaplan, Alicja, Kasperska-Zając, Constance, Katelaris, Aharon, Kessel, Andreas, Kleinheinz, Emek, Kocatürk, Mitja, Košnik, Dorota, Krasowska, Kanokvalai, Kulthanan, M Sendhil, Kumaran, José Ignacio, Larco Sousa, Hilary J, Longhurst, William, Lumry, Andrew, MacGinnitie, Markus, Magerl, Michael P, Makris, Alejandro, Malbrán, Alexander, Marsland, Inmaculada, Martinez-Saguer, Iris V, Medina, Raisa, Meshkova, Martin, Metz, Iman, Nasr, Jan, Nicolay, Chikako, Nishigori, Isao, Ohsawa, Kemal, Özyurt, Nikolaos G, Papadopoulos, Claudio A S, Parisi, Jonathan Grant, Peter, Wolfgang, Pfützner, Todor, Popov, Nieves, Prior, German D, Ramon, Adam, Reich, Avner, Reshef, Marc A, Riedl, Bruce, Ritchie, Heike, Röckmann-Helmbach, Michael, Rudenko, Andaç, Salman, Mario, Sanchez-Borges, Peter, Schmid-Grendelmeier, Faradiba S, Serpa, Esther, Serra-Baldrich, Farrukh R, Sheikh, William, Smith, Angèle, Soria, Petra, Staubach, Urs C, Steiner, Marcin, Stobiecki, Gordon, Sussman, Anna, Tagka, Simon Francis, Thomsen, Regina, Treudler, Solange, Valle, Martijn, van Doorn, Lilian, Varga, Daniel O, Vázquez, Nicola, Wagner, Liangchun, Wang, Christina, Weber-Chrysochoou, Young-Min, Ye, Anna, Zalewska-Janowska, Andrea, Zanichelli, Zuotao, Zhao, Yuxiang, Zhi, Torsten, Zuberbier, Ricardo D, Zwiener, and Anthony, Castaldo

Subjects
Urticaria, Humans, Angioedema
Published
2020

20. Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases

Author

José M. Mascaró, Ignasi Figueras-Nart, José Hernández-Rodríguez, and Xavier Solanich

Subjects
0301 basic medicine, Urticaria, Biopsy, Autoimmunity, Dermatitis, Review, 0302 clinical medicine, Maculopapular rash, Immunology and Allergy, dermatopathology, Skin, Skin manifestations, maculopapular rash, monogenic autoinflammatory diseases, Dermatologia, Inflamació, clinical dermatology, Phenotype, classification, Dermatopathology, Symptom Assessment, medicine.symptom, Vasculitis, Urticària, lcsh:Immunologic diseases. Allergy, medicine.medical_specialty, Immunology, Dermatology, Autoimmune Diseases, Diagnosis, Differential, Lesion, 03 medical and health sciences, medicine, Humans, Genetic Predisposition to Disease, Genetic Association Studies, Inflammation, business.industry, autoinflammatory diseases, medicine.disease, 030104 developmental biology, Cutaneous Involvement, Subcutaneous nodule, urticarial rash, lcsh:RC581-607, Panniculitis, business, Biomarkers, 030215 immunology
Abstract

Autoinflammatory diseases include disorders with a monogenic cause and also complex conditions associated to polygenic or multifactorial factors. An increased number of both monogenic and polygenic autoinflammatory conditions have been identified during the last years. Although skin manifestations are often predominant in monogenic autoinflammatory diseases, clinical and histopathological information regarding their dermatological involvement is still scarce. Monogenic autoinflammatory diseases with cutaneous expression can be classified based on the predominant lesion: (1) maculopapular rashes or inflammatory plaques; (2) urticarial rashes; (3) pustular, pyogenic or neutrophilic dermatosis-like rashes; (4) panniculitis or subcutaneous nodules; (5) vasculitis or vasculopathy; (6) hyperkeratotic lesions; (7) hyperpigmented lesions; (8) bullous lesions; and (9) aphthous lesions. By using this classification, this review intends to provide clinical and histopathological knowledge about cutaneous involvement in monogenic autoinflammatory diseases.

Published
2019
Full Text
View/download PDF

21. Atopic Dermatitis: From Physiopathology to the Clinics

Author

Oscar Palomares-Gracia and Ignasi Figueras-Nart

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL, Atopic dermatitis, medicine.disease, Dermatology, Pathophysiology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine, business, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Atopic dermatitis is a chronic, pruritic, relapsing inflammatory disease with a complex etiopathogenesis. Alterations of the epidermal barrier function together with a predominantly type 2 altered immune response are responsible for the heterogeneous clinical manifestation. Although pruritic eczematous plaques represent the most frequent phenotype, several others are also characteristic. The diagnostic of the disease relies on clinical aspects, and no complimentary tests are needed. In the literature, we can find a significant number of diagnostic and screening biomarkers; however, severity ones are the most reliable and applicable. Patient-tailored treatment is mandatory, as not all the patients equally respond to the same drugs. The newly released therapies, as well as those under investigation, give hope to AD patients.

Published
2019

22. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series

Author

Joaquín Sastre, Antonio Valero, J.F. Silvestre, Ricardo Ruiz-Villaverde, P. Herranz‐Pinto, José Juan Pereyra-Rodríguez, Laia Curto-Barredo, Leandro Martinez-Pilar, F.J. Ortiz‐de‐Frutos, L. Herraez‐Herrera, Ignasi Figueras-Nart, E Serra-Baldrich, I. Jáuregui‐Presa, J.C. Armario-Hita, and R. Izu‐Belloso

Subjects
Moderate to severe, Adult, Male, medicine.medical_specialty, Adolescent, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Dermatitis, Atopic, Young Adult, Quality of life, Severity of illness, medicine, Humans, Young adult, Aged, Retrospective Studies, business.industry, Pruritus, Retrospective cohort study, Atopic dermatitis, Middle Aged, medicine.disease, Conjunctivitis, Dupilumab, Clinical Practice, Treatment Outcome, Quality of Life, Female, business, Follow-Up Studies
Published
2019

23. Langerhans cell histiocytosis presenting as fingernail changes

Author

Asunción Vicente, Cristina Jou-Muñoz, Julia María Sánchez-Schmidt, Ofelia Cruz-Martinez, Ignasi Figueras-Nart, Veronica Paola Celis-Passini, Maria Antonia González-Ensenyat, and Xavier Bordas-Orpinell

Subjects
medicine.medical_specialty, business.industry, Mortality rate, Langerhans cell histiocytosis, Case Report, Dermatology, Disease, Prognostic factors, medicine.disease, Multisystem disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Nail (anatomy), medicine, Ungles -- Malalties, LCH, Langerhans cell histiocytosis, Nail involvement, business
Abstract

Langerhans cell histiocytosis (LCH) identifies a spectrum of disorders that are classified according to the organs involved (single- or multi-organ disease) and the presence or absence of organ failure. Patients younger than 2 years with a multisystem disease have a significantly higher mortality rate than older children.1 Nail involvement in LCH is extremely uncommon and rarely reported. To our knowledge, 18 cases have been documented in the literature to date. According to most cases reported, it is thought to indicate a poor prognosis.2, 3, 4, 5, 6 We report the case of a child with nail lesions, which led to a diagnosis of LCH.

Published
2016
Full Text
View/download PDF

24. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Author

N Lamas-Domenech, M Villar, Xavier Cubiró, E Serra-Baldrich, Vicente Expósito-Serrano, C Baliu-Piqué, Laia Curto-Barredo, Gemma Melé-Ninot, X Duran-Jordà, M. Bonfill-Ortí, J. Spertino, I Bielsa-Marsol, G Aparicio, X García-Navarro, A Álvarez, Ana Giménez-Arnau, M. Vilavella, A. Guilabert, J Garcias-Ladaria, and Ignasi Figueras-Nart

Subjects
Adult, medicine.medical_specialty, Urticaria, Treatment outcome, Drug Resistance, Dermatology, Omalizumab, Disease activity, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, Anti-Allergic Agents, Medicine, Humans, In patient, Retrospective Studies, Dose-Response Relationship, Drug, business.industry, Urticària -- Tractament, Age Factors, Retrospective cohort study, Middle Aged, Treatment Outcome, 030228 respiratory system, Multicenter study, Chronic Disease, Female, business, medicine.drug
Published
2018

25. Actinic Keratosis, a Chronic, Progressive Disease: Understanding Clinical Gaps to Optimise Patient Management

Author

Rino Cerio, Ignasi Figueras Nart, Thomas Dirschka, Giovanni Pellacani, Brigitte Dréno, Andrés Ruiz de Casas, John T. Lear, and Ketty Peris

Subjects
0301 basic medicine, 030103 biophysics, medicine.medical_specialty, Consensus, Skin Neoplasms, Keratosis, Treatment outcome, MEDLINE, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Risk Factors, Severity of illness, lcsh:Dermatology, actinic keratosis, Medicine, Humans, Tumors, integumentary system, business.industry, Actinic keratosis, General Medicine, lcsh:RL1-803, medicine.disease, Professional Practice Gaps, Patient management, Skin diseases, Keratosis, Actinic, Treatment Outcome, Malalties de la pell, Predictive value of tests, Chronic Disease, Practice Guidelines as Topic, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Progressive disease
Abstract

Actinic keratosis (AK) is a chronic, progressive disease of the skin that has undergone long-term sun exposure. The affected areas contain visible and subclinical nonvisible sun damage resulting in epidermal keratinocyte dysplasia, known by many as ‘field cancerisation’ (1), which is prone to AKs and sun-related skin cancer (2). Thus, visible AKs are clinical biomarkers for a photo-damaged field with subclinical damage associated with the unpredictable risk of progression to invasive squamous cell carcinoma (iSCC) (3). The aim of this multiexpert opinion article is to provide a discussion succinctly highlighting the clinical gaps for optimal management of AK: the lack of a universal definition and the need for a standardised grade assessment of AK/field cancerisation that also takes into account individual risk.

Published
2017

26. Escleromixedema

Author

Anna Serra, Sara Gómez Armayones, and Ignasi Figueras Nart

Subjects
business.industry, Medicine, Dermatology, business
Published
2014
Full Text
View/download PDF

27. Pioderma gangrenoso

Author

Alba Álvarez-Abella, Ignasi Figueras Nart, Anna Serra, and Sara Martín-Sala

Subjects
business.industry, Medicine, Dermatology, business
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results